Adrenaline (epinephrine)
Brand names: EpiPen, Emerade, Jext
Adrenaline (epinephrine) is an endogenous catecholamine used in emergency care, principally in cardiac arrest and as a vasopressor in shock, and intramuscularly in anaphylaxis.
Adult dose
Paediatric dose
Dose adjustments
No renal dose adjustment is given in the fetched sections. §4.4 lists severe renal impairment among the conditions in which adrenaline should be used with caution, and notes that prolonged administration may induce metabolic acidosis, renal necrosis and tachyphylaxis. The US label adds (§5.5) that epinephrine constricts renal blood vessels, which may result in oliguria or renal impairment.
Not stated — the fetched UK SPC sections contain no hepatic impairment dosing statement.
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Hypersensitivity to the active substance or to any of the excipients — but note the SPC's own qualifier, VERBATIM §4.3: 'Contraindications are relative as this product is intended for use in life-threatening emergencies.'
- Use in fingers, toes, ears, nose, genitalia or buttocks owing to the risk of ischaemic tissue necrosis (§4.3)
- Do not use if the solution is discoloured (§4.3)
- Do not give the 1 mg/ml (1:1000) solution intravenously — §4.2/§4.4: intravenous administration of adrenaline for anaphylaxis requires a 1:10,000 (0.1 mg/ml) solution
- Note: the US label in this bundle states 'CONTRAINDICATIONS None.' — the entries above are from the UK SPC and are the ones that apply in UK practice
Side effects
- Cardiac: palpitations, tachycardia; in high dosage or in sensitive patients — cardiac dysrhythmia (sinus tachycardia, ventricular fibrillation/cardiac arrest), acute angina attacks and risk of acute myocardial infarction (§4.8)
- Vascular: pallor, coldness of the extremities; in high dosage or in sensitive patients — hypertension (with risk of cerebral haemorrhage) and vasoconstriction, for example cutaneous, in the extremities or kidneys (§4.8)
- Nervous system: headache, tremors, dizziness, syncope; in patients with Parkinsonian syndrome adrenaline increases rigidity and tremor (§4.8)
- Psychiatric: anxiety, nervousness, fear, hallucinations (§4.8)
- Metabolic: hyperglycaemia, hypokalaemia, metabolic acidosis (§4.8)
- Gastrointestinal: nausea, vomiting (§4.8)
- Respiratory: dyspnoea (§4.8)
- Eye: mydriasis (§4.8)
- General: sweating, weakness; repeated local injections may produce necrosis at sites of injection as a result of vascular constriction (§4.8)
- All the above are listed at 'Frequency not known' in the SPC — the occurrence of undesirable effects depends on the sensitivity of the individual patient and the dose involved
- US label §6 additionally lists, from infusion use: supraventricular tachycardia, ventricular arrhythmias, myocardial ischaemia, myocardial infarction, limb ischaemia, pulmonary oedema, extravasation and tissue necrosis, chest pain, hypoglycaemia/hyperglycaemia, insulin resistance, lactic acidosis, stroke, central nervous system bleeding, paraesthesia and renal insufficiency
Monitoring
- VERBATIM §4.2: 'The patient should be monitored as soon as possible (pulse, blood pressure, ECG, pulse oximetry). This will help monitor the response to adrenaline.'
- §4.4: 'This product is for emergency use only and medical supervision of the patients is necessary after administration.'
- Blood glucose — §4.4: 'Adrenaline may cause or exacerbate hyperglycaemia, blood glucose should be monitored, particularly in diabetic patients.'
- Inspect the injection site — repeated local administration may produce necrosis at the sites of injection (§4.4)
- US label §5.1: 'Because individual response to epinephrine may vary significantly, monitor blood pressure frequently and titrate to avoid excessive increases in blood pressure.' §5.4 (IV infusion use): check the infusion site frequently for free flow to avoid extravasation and local necrosis
Clinical monograph
How it works
It is a potent agonist at alpha- and beta-adrenergic receptors, producing vasoconstriction, increased myocardial contractility and heart rate, and bronchodilation.
Prescribing in practice
- Different clinical situations require very different concentrations and routes, so the correct strength must be confirmed against the indication, as confusion between intramuscular anaphylaxis and intravenous cardiac-arrest preparations can be fatal.
- In cardiac arrest it is given intravenously or intraosseously during CPR per the resuscitation algorithm; as a peripheral vasopressor infusion it risks extravasation and tissue necrosis.
- Effects are exaggerated in patients on non-selective beta-blockers or tricyclic antidepressants and it may provoke arrhythmias and severe hypertension.
Monitoring
Continuous ECG, blood pressure and, for infusions, invasive arterial and central access monitoring with frequent checks of the infusion site are required.
Counselling the patient
- Confirm the indication-specific concentration and route before administration.
- Give vasopressor infusions through a central line where feasible to limit extravasation injury.
- Document timing of doses against the resuscitation cycle.
Evidence & guidelines
Adrenaline is recommended in Resuscitation Council UK advanced life support algorithms for cardiac arrest and as a first-line agent in anaphylaxis.
Reference: Resuscitation Council UK 2021; NICE CG134; MHRA DSU on auto-injectors; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- C-Peptide to Glucose Ratio · Diabetes Classification
- International Staging System (ISS) for Multiple Myeloma · Multiple Myeloma
- Revised ISS (R-ISS) for Multiple Myeloma · Haematological Malignancy
- International Staging System for Multiple Myeloma (ISS) · Oncology
- Paracetamol overdose · TOXBASE/NPIS; MHRA DSU 2012/2024; SNAP regimen (Lancet 2014)
- TCA overdose · TOXBASE/NPIS; AACT/EAPCCT position statements; Resuscitation Council UK ALS
- Opioid overdose · TOXBASE/NPIS; Resuscitation Council UK
- Anticholinergic toxidrome · TOXBASE/NPIS; AACT/EAPCCT
- Benzodiazepine overdose · TOXBASE/NPIS; AACT/EAPCCT
- β-blocker overdose · TOXBASE/NPIS; AACT/EAPCCT; ESC